BioNTech's revenue soared during the COVID era, but the company faces uncertainty with declining vaccine sales and plans for new oncology-focused products. The company is shifting focus to oncology ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

June 12 (Reuters) - German biotech firm BioNTech (22UAy.DE), opens new tab has agreed to acquire domestic peer CureVac (5CV.DE), opens new tab for about $1.25 billion worth of BioNTech shares, it said ...

The Company expects its revenues for the full 2024 financial year to be at the low end of the guidance range provided in its outlook: Total revenues for the 2024 financial year low end of €2.5 billion ...

Company is suing pharmaceutical rival and its German partner for patent infringement Moderna is suing its US pharmaceutical rival Pfizer and its German partner BioNTech for patent infringement in the ...

BioNTech recently showcased its AI capabilities through its subsidiary InstaDeep during its Innovation Series AI Day, emphasizing new advancements in artificial intelligence applications for drug ...

BioNTech (BNTX) - the messenger-RNA pioneer that partnered with pharma giant Pfizer (PFE) on the Comirnaty COVID vaccine - announced its Q422 and FY22 earnings earlier today, as well as updating on ...

Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve ...

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a ...

Shares of BioNTech SE – ADR (NASDAQ:BNTX) fell 5.7% to $115.84 on Monday, part of a broader decline in vaccine stocks triggered by Moderna's updated revenue guidance for 2025, which fell below analyst ...

The Germany company BioNTech has achieved a breakthrough with its COVID-19 vaccine. Now it is faced with the task of becoming a global corporation, but it faces stiff competition from Big Pharma. A ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The call came last Sunday evening, as Ugur Sahin and Ozlem Tureci were catching up with paperwork at their ...